Targeted Immune Modulation
Cross-source consensus on Targeted Immune Modulation from 1 sources and 5 claims.
1 sources · 5 claims
Uses
Benefits
Evidence quality
Highlighted claims
- European Society of Cardiology atrial fibrillation guidelines do not recommend immunomodulators because positive randomized controlled trials are lacking. — Identification of immunomodulators associated with atrial fibrillation reporting to better understand AF immunologic mechanisms: a Vigibase retrospective disproportionality analysis and a literature review
- No definitive druggable immune target for atrial fibrillation has been identified. — Identification of immunomodulators associated with atrial fibrillation reporting to better understand AF immunologic mechanisms: a Vigibase retrospective disproportionality analysis and a literature review
- A randomized trial of methylprednisolone found no significant difference in atrial fibrillation recurrence after 24 months. — Identification of immunomodulators associated with atrial fibrillation reporting to better understand AF immunologic mechanisms: a Vigibase retrospective disproportionality analysis and a literature review
- Colchicine has shown effectiveness in atrial fibrillation prevention, especially after pulmonary vein isolation, but adverse drug reactions limit its use. — Identification of immunomodulators associated with atrial fibrillation reporting to better understand AF immunologic mechanisms: a Vigibase retrospective disproportionality analysis and a literature review
- Future targeted immune modulation around ablation could focus on IL-6 and IL-11 pathways, especially in persistent atrial fibrillation. — Identification of immunomodulators associated with atrial fibrillation reporting to better understand AF immunologic mechanisms: a Vigibase retrospective disproportionality analysis and a literature review